Suppr超能文献

产碳青霉烯酶弗氏柠檬酸杆菌序列型22高风险国际克隆株的全球出现与传播动态:一项回顾性基因组流行病学研究

Global emergence and transmission dynamics of carbapenemase-producing Citrobacter freundii sequence type 22 high-risk international clone: a retrospective, genomic, epidemiological study.

作者信息

Wang Qiaojun, Zhou Longjie, Chen Xiaoling, Yao Jiayao, Sun Xinran, Peng Kai, Gao Yanyun, Feil Edward J, Yu Yunsong, Wang Zhiqiang, Li Ruichao, Li Xi

机构信息

Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, China.

Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

出版信息

Lancet Microbe. 2025 Jul 16:101149. doi: 10.1016/j.lanmic.2025.101149.

Abstract

BACKGROUND

Carbapenemase-producing Citrobacter (CPC) species have recently been recognised as emerging pathogens associated with nosocomial infections in humans. The increased rate of Citrobacter freundii infections is a public health concern and there is a paucity of genomic data regarding its global transmission dynamics. We aimed to characterise the genetic features of CPC species, and their associated carbapenemase-encoding plasmids, obtained from hospitalised patients in China and from publicly available global data, with a particular focus on high-risk clones.

METHODS

This was a retrospective, genomic epidemiological study of CPC species obtained from a tertiary hospital in Zhejiang Province, China, from March 5, 2013, to March 5, 2023. We used antimicrobial susceptibility testing, short-read and long-read whole-genome sequencing, phylogenomic analysis, and plasmid structure analysis. A global dataset of complete plasmid sequences encoding bla, bla, and bla was constructed from the National Center for Biotechnology Information (NCBI) RefSeq database to provide insights into their diversity and distribution. All carbapenemase-producing Citrobacter freundii genomes from the NCBI GenBank database were incorporated in the comparative genomic analyses. Bayesian phylogeographical analysis and growth rate assays were carried out to characterise the high-risk C freundii sequence type (ST) 22 clone.

FINDINGS

1724 Citrobacter species isolates were collected from diverse clinical specimens, with 48 identified as CPC species. Citrobacter koseri (22 [46%] of 48) and C freundii (20 [42%]) were the predominant CPC species. Comparative analysis found C freundii carried significantly higher median numbers of plasmid replicons (5·0 [IQR 3·3-6·0] vs 2·0 [2·0-3·0]; p<0·0001) and acquired antimicrobial resistance genes (12·0 [7·3-15·8] vs 3·0 [3·0-5·3]; p<0·0001) than did C koseri. Molecular characterisation identified Inc-type plasmids, In823::Kl.pn.I3/In1589-like/In837-like integrons, Tn6296/Tn125/Tn5060 transposons, and insertion sequences (eg, IS26, IS3000, IS5, ISAba125, ISCR1), collectively facilitating the dissemination of carbapenemase genes. Global analysis of 3126 carbapenemase-encoding plasmids found epidemic plasmids with broad host ranges and global diversity. Phylogenetic investigation of predominant carbapenemase-encoding plasmids showed their persistence across geographical regions, temporal spans, and Enterobacterales species, exhibiting high genetic similarity to our clinical plasmids. A phylogenetic tree of 726 global carbapenemase-producing C freundii genomes showed that ST22 (227 [31·3%]) represents the predominant multidrug-resistant clone across community, health-care, and environmental niches. Transmission across continents contributes to the global predominance of the ST22 clone, which carries a high load of resistance genes (median 15·0 [IQR 11·0-17·0] vs 12·0 [3·0-16·0]; p<0·0001) and enhanced plasmid maintenance capacity (median replicons 5·0 [IQR 4·0-7·0] vs 4·0 [3·0-6·0]; p<0·0001) relative to non-ST22 clones.

INTERPRETATION

Our study provides evidence to suggest that Citrobacter species are emerging carriers of carbapenem-resistance genes. These findings provide insight into the population structure of CPC species and highlight C freundii ST22 as a prominent high-risk international clone.

FUNDING

National Natural Science Foundation of China, National Health Commission Scientific Research Fund-Zhejiang Provincial Major Health Science and Technology Plan Project, Zhejiang Province Natural Science Foundation Project, Outstanding Youth Foundation of Jiangsu Province of China, the Priority Academic Program Development of Jiangsu Higher Education Institutions, and Postgraduate Research and Practice Innovation Program of Jiangsu Province.

摘要

背景

产碳青霉烯酶柠檬酸杆菌(CPC)最近被认为是与人类医院感染相关的新兴病原体。弗氏柠檬酸杆菌感染率的上升是一个公共卫生问题,关于其全球传播动态的基因组数据匮乏。我们旨在表征从中国住院患者以及公开可得的全球数据中获得的CPC物种及其相关的碳青霉烯酶编码质粒的遗传特征,特别关注高风险克隆。

方法

这是一项对2013年3月5日至2023年3月5日从中国浙江省一家三级医院获得的CPC物种进行的回顾性基因组流行病学研究。我们使用了抗菌药物敏感性测试、短读长和长读长全基因组测序、系统发育基因组分析和质粒结构分析。从美国国立生物技术信息中心(NCBI)的RefSeq数据库构建了一个编码bla、bla和bla的完整质粒序列的全球数据集,以深入了解它们的多样性和分布。将来自NCBI GenBank数据库的所有产碳青霉烯酶弗氏柠檬酸杆菌基因组纳入比较基因组分析。进行了贝叶斯系统发育地理分析和生长速率测定,以表征高风险弗氏柠檬酸杆菌序列类型(ST)22克隆。

结果

从各种临床标本中收集了1724株柠檬酸杆菌分离株,其中48株被鉴定为CPC物种。科氏柠檬酸杆菌(48株中的22株[46%])和弗氏柠檬酸杆菌(20株[42%])是主要的CPC物种。比较分析发现,弗氏柠檬酸杆菌携带的质粒复制子中位数(5.0[四分位间距3.3 - 6.0]对2.0[2.0 - 3.0];p<0.0001)和获得的抗菌药物耐药基因(12.0[7.3 - 15.8]对3.0[3.0 - 5.3];p<0.0001)显著高于科氏柠檬酸杆菌。分子特征鉴定出Inc型质粒、In823::Kl.pn.I3/In1589样/In837样整合子、Tn6296/Tn125/Tn5060转座子和插入序列(如IS26、IS3000、IS5、ISAba125、ISCR1),共同促进了碳青霉烯酶基因的传播。对3126个碳青霉烯酶编码质粒的全球分析发现了具有广泛宿主范围和全球多样性的流行质粒。对主要碳青霉烯酶编码质粒的系统发育研究表明,它们在地理区域、时间跨度和肠杆菌科物种中持续存在,与我们的临床质粒具有高度遗传相似性。726个全球产碳青霉烯酶弗氏柠檬酸杆菌基因组的系统发育树表明,ST22(227株[31.3%])是社区、医疗保健和环境生态位中主要的多重耐药克隆。跨洲传播导致了ST22克隆在全球的优势地位,相对于非ST22克隆,它携带高负荷的耐药基因(中位数15.0[四分位间距11.0 - 17.0]对1十二点零[3.0 - 16.0];p<0.0001)和增强的质粒维持能力(中位数复制子5.0[四分位间距4.0 - 7.0]对4.0[3.0 - 6.0];p<0.0001)。

解读

我们的研究提供了证据表明柠檬酸杆菌物种是碳青霉烯耐药基因的新兴携带者。这些发现深入了解了CPC物种的种群结构,并突出了弗氏柠檬酸杆菌ST22作为一个突出的高风险国际克隆。

资助

中国国家自然科学基金、国家卫生健康委科研基金 - 浙江省重大卫生科技计划项目、浙江省自然科学基金项目、中国江苏省杰出青年基金、江苏省高等学校优势学科建设工程、江苏省研究生科研与实践创新计划。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验